{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:49Z","timestamp":1788932389749,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejca.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T11:28:39Z","timestamp":1604748519000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer"],"prefix":"10.1016","volume":"141","author":[{"given":"Xingzhou","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-7398","authenticated-orcid":false,"given":"Analyn","family":"Lizaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.005_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.10.005_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib3","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0b013e31829f684a","article-title":"Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib5","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","article-title":"The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.005_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2020.10.005_bib7","doi-asserted-by":"crossref","first-page":"E542","DOI":"10.21037\/jtd.2016.05.95","article-title":"Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report","volume":"8","author":"Wang","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2020.10.005_bib8","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/JTO.0000000000000538","article-title":"Uncommon EGFR exon 19 mutations confer gefitinib resistance in advanced lung adenocarcinoma","volume":"10","author":"Coco","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1158\/1078-0432.CCR-11-2361","article-title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma","volume":"18","author":"He","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.005_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jtho.2016.11.2235","article-title":"Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer","volume":"12","author":"Mao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib12","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jtho.2017.05.011","article-title":"Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small cell lung cancer","volume":"12","author":"Wan","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2018.07.101","article-title":"The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer","volume":"13","author":"Laufer-Geva","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.10.005_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002199","article-title":"Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study","volume":"13","author":"Pecuchet","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.10.005_bib16","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-11-2353","article-title":"Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR","volume":"18","author":"Chung","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.005_bib17","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.18632\/oncotarget.3472","article-title":"Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer","volume":"6","author":"Tsigelny","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.10.005_bib18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2020.10.005_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejca.2020.10.005_bib20","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.10.005_bib21","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.10.005_bib22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Canc Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920310613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:27Z","timestamp":1760733027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920310613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"alternative-id":["S0959804920310613"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}